Oral misoprostol as first-line care for incomplete abortion in Burkina Faso  by Blandine, Thieba et al.
International Journal of Gynecology and Obstetrics 119 (2012) 166–169
Contents lists available at SciVerse ScienceDirect
International Journal of Gynecology and Obstetrics
j ourna l homepage: www.e lsev ie r .com/ locate / i jgoCLINICAL ARTICLE
Oral misoprostol as ﬁrst-line care for incomplete abortion in Burkina Faso
Thieba Blandine a, Adama Z. Ouattara b, Angela Coral c, Cisse Hassane b, Hien Clotaire d, Blami Dao e,
Jean Lankoande a, Ayisha Diop c, Jennifer Blum c,⁎
a Yalgado Ouédraogo University Teaching Hospital, Ouagadougou, Burkina Faso
b Dandé District Hospital, Dandé, Burkina Faso
c Gynuity Health Projects, New York, USA
d Ziniaré District Hospital, Ziniaré, Burkina Faso
e Souro Sanou University Teaching Hospital, Bobo Dioulasso, Burkina Faso⁎ Corresponding author at: Gynuity Health Projects, 1
10010, USA. Tel.: +1 212 448 1230; fax: +1 212 448 1
E-mail address: jblum@gynuity.org (J. Blum).
0020-7292/$ – see front matter © 2012 International Fed
doi:10.1016/j.ijgo.2012.05.036a b s t r a c ta r t i c l e i n f oArticle history:
Received 17 January 2012
Received in revised form 23 May 2012
Accepted 18 July 2012
Keywords:
Incomplete abortion
Mid-level providers
Misoprostol
Postabortion care
Objective: To explore 400-μg sublingual misoprostol as primary treatment in lower-level facilities with no
previous experience providing postabortion care.Methods:Women presenting with incomplete abortion were
offered a single dose of 400-μg sublingual misoprostol. Incomplete abortion was deﬁned as uterine size consis-
tent with fewer than 12 weeks of gestation, open cervical os, and reports of past or present history of vaginal
bleeding. Women returned to the clinic 1 week after misoprostol administration for follow-up. At that time,
they were discharged if the uterine evacuationwas a success or were offered a second follow-up visit or surgical
completion if still incomplete. Results: One-hundred women received misoprostol; outcome data were
unavailable for 1 woman. Complete uterine evacuation was achieved for 97 (98.0%) women. Satisfaction was
high, with nearly all women indicating that they were “satisﬁed” (n=57 [57.6%]) or “very satisﬁed” (n=41
[41.4%]) with their experience. Adverse effects were considered “tolerable” by 72 of 97 (74.2%) women.
Ninety-seven of 99 (98.0%) participants indicated that they would choose misoprostol for incomplete abortion
care in the future and 95 of 97 (97.9%) stated that they would recommend it to a friend. Conclusion:Misoprostol
is a viable option for treatment of incomplete abortion at mid-level facilities.
Clinical trials.gov: NCT00466999.
© 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
In limited-resource settings, the low cost, stability at ambient tem-
peratures, and increasing availability of misoprostol have contributed
to its appeal as a viable alternative to surgical treatment of incomplete
abortion. Incomplete abortion, which can result from spontaneous or
induced pregnancy loss, occurs when the products of conception are
not completely expelled from the uterus. Left untreated, incomplete
abortion may lead to a variety of complications and contributes to
abortion-relatedmorbidities. Surgical treatment is highly effective; how-
ever, the need for skilled, trained providers and special equipment is a
limiting factor in many limited-resource settings [1,2]. Treatment with
misoprostol eliminates some of these preconditions—such as the need
for special surgical equipment—while maintaining a high safety and
efﬁcacy proﬁle.
Numerous studies have conﬁrmed that 600-μg oral misoprostol
safely and effectively evacuates the uterus in 91%–99% of women [3–6].
One study comparing 600-μg oral and 400-μg sublingual misoprostol
concluded that the 2 doses were similarly effective [7]. A more recent5 E. 26th Street, New York, NY
260.
eration of Gynecology and Obstetrics.study comparing 400μg sublingually with manual vacuum aspiration
(MVA) in 2 Egyptian hospitals provided further evidence that the sublin-
gual dose works well: 98.3% of participants experienced complete uter-
ine evacuation with the regimen [8]. Data from this study and others
show that misoprostol is analogous to MVA as ﬁrst-line treatment for
incomplete abortion [8]. In 2009, WHO added misoprostol to its Model
List of Essential Medicines for the treatment of spontaneous and incom-
plete abortion, remarking that the “evidence showed that misoprostol
is as effective as surgery and in some settings may be safer as well as
cheaper” [9].
The aim of the present study was to investigate the use of 400-μg
sublingual misoprostol as primary treatment for uterine evacuation at
lower-level facilities with no previous experience in postabortion
care. Providing misoprostol treatment where no other services exist
has the potential to increase availability and access to safe and effec-
tive care for incomplete abortion.
2. Materials and methods
Between September 29, 2008, and November 30, 2009, women
presenting with incomplete abortion were enrolled at 2 district
hospitals (in Dandé and Ziniaré) in Burkina Faso, West Africa. Pro-
viders at these facilities had not previously offered postabortion carePublished by Elsevier Ireland Ltd. All rights reserved.
Treated with 400-µg
sublingual misoprostol:
n=100
Eligible: n=100
Recruited: n=100
Data analyzed: n=100 
Outcome data not available: n=1
Lost to follow-up: n=0
Fig. 1. Participant ﬂow.
Table 1
Participant characteristics (n=100).a
Characteristic Misoprostol
Age, y (n=73) 26±7
Parity (n=73) 2±2
Education (n=79)
Primary 13 (16.5)
Secondary 15 (19.0)
None 51 (64.6)
Currently married (n=99) 79 (79.8)
Woman's report of current abortion (n=97)
Spontaneous 89 (91.8)
Induced 8 (8.2)
Provider's assessment of current abortion (n=92)
Spontaneous 78 (84.8)
Induced 14 (15.2)
a Values are given as mean±SD or number (percentage).
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facility. Neither facility had ultrasound services, so referral was also
the norm for ultrasonography. Both hospitals were adequately staffed
with physicians, nurses, and nurse–midwives. Neither had trained
obstetrician–gynecologists.
All women presenting with incomplete abortion were eligible to
participate. Incomplete abortion was assessed clinically to ascertain
open cervical os, uterine size consistent with fewer than 12 weeks
of gestation, and past or present history of vaginal bleeding during
pregnancy. Ultrasound conﬁrmation of incomplete abortion was not
stipulated in the protocol but women could be referred elsewhere
for ultrasound if providers were unsure of abortion status. Women
were excluded if they presented with a known allergy to misoprostol
or other prostaglandins, suspicion of ectopic pregnancy, signs of peri-
tonitis and/or sepsis, hemodynamic instability, or shock.
All eligible women were given the option of participating in the
study and receiving misoprostol as ﬁrst-line care, or receiving stan-
dard referral to the closest tertiary-level hospital (in either Bobo
Dioulasso or Ouagadougou). Women who agreed to participate con-
sented via signature or thumbprint after information was provided
verbally and in writing by study staff. The study was approved by
the Burkina Faso Ministry of Health Ethical Review Board.
Enrolled women were given a single dose of 400-μg misoprostol
(Cytotec; Pﬁzer, New York, NY, USA) to administer sublingually.
Women administered the tablets at the study hospital and remained
under observation for between 30 minutes and 2 hours to document
any adverse effects. All participants received paracetamol to manage
their pain, if needed. Each woman was scheduled for a follow-up
visit 1 week later to assess the status of their incomplete abortion
via clinical examination. If the uterine evacuation was complete at
the 1-week follow-up, the woman was discharged from the study.
If, on clinical examination, there was evidence of retained products
of conception requiring additional care, women were given the op-
tion of waiting an additional week to see whether the retained prod-
ucts would evacuate on their own or being referred to a tertiary-level
facility for standard surgical completion. Every effort was made to
contact—in a conﬁdential manner—women not returning for follow-up.
In addition, at the time of discharge, all participants were asked about
their satisfaction with the treatment given and whether they would
use the method again if necessary.
The primary outcome was complete uterine evacuation (clinically
assessed by resolution of the signs/symptoms of incomplete abortion
clinically consistent with a completed abortion), without recourse to
additional intervention. Secondary outcomes—including reports of
adverse effects, satisfaction, and acceptability—were also recorded.
All data were entered, cleaned, and analyzed using SPSS version 15
(IBM, Armonk, NY, USA).
3. Results
In total, 100 women were given misoprostol for treatment of in-
complete abortion in the study. No women were lost to follow-up
but outcome data were unavailable for 1 woman (all available data
shown). Fig. 1 outlines the ﬂow of participants. On average, partici-
pants were 26±7 years of age, with 51 of 79 (64.6%) indicating no
formal education (Table 1). Seventy-nine (79.8%) women were cur-
rently married. When asked about their current abortion, 89 of 97
(91.8%) women reported that they were experiencing a spontaneous
abortion.
Complete uterine evacuation was achieved for 97 (98.0%) women
(Table 2); 86 (86.9%) achieved complete evacuation at their initial
1-week follow-up visit. Two (2.0%) of the 99 women underwent
surgical completion after their abortion status was determined as
incomplete or uncertain. Ultrasound was performed for only 6 of
84 (7.1%) women to conﬁrm complete uterine evacuation. Of the 2
failed evacuations, 1 woman's abortion status was determined to beuncertain at her initial 1-week follow-up visit and she agreed to re-
turn to the hospital a week later for a second visit. Between study
visits, a provider at another facility performed an MVA. In the other
case, the woman still had retained products of conception at her sec-
ond follow-up visit and was subsequently referred to another facility,
where MVA was performed.
Fifty-seven (57.6%) and 41 (41.4%) participants rated their overall
satisfaction with treatment as “satisﬁed” and “very satisﬁed,” respec-
tively. Seventy-two of 97 (74.2%) rated their overall experience with
adverse effects as “tolerable” (Table 2). Thirty-eight (38.0%) women
reported normal bleeding (like menses) and 31 (31.0%) reported heavy
bleeding (greater than menses). When asked about perception and
acceptability of the amount of bleeding, 62 (62.0%) reported that it was
less than expected and 76 (76.0%) rated the amount as “acceptable.”
Other adverse effects reported included abdominal pain (n=53
[53.0%]), fever/chills (n=8 [8.0%]), nausea (n=7 [7.0%]), and vomiting
Table 2
Efﬁcacy rates, adverse effects, acceptability, and satisfaction (n=100).a
Misoprostol
Efﬁcacy rates b
Lost to follow-up 0/100 (0.0)
Overall success rate 97/99 (98.0)
Failure rate 2/99 (2.0)
Ultrasound used to assess outcome 6/84 (7.1)
Overall experience with adverse effects (n=97)
Very tolerable 13 (13.4)
Tolerable 72 (74.2)
Severe 1 (1.0)
Very severe 0 (0.0)
No adverse effects 11 (11.3)
Bleeding
Heavy bleeding (greater than menses) 31 (31.0)
Normal bleeding (like menses) 38 (38.0)
Spotting (less than menses) 11 (11.0)
Other adverse effects
Nausea 7 (7.0)
Vomiting 4 (4.0)
Abdominal pain 53 (53.0)
Fever/chills 8 (8.0)
Overall satisfaction (n=99)
Very satisﬁed 41 (41.4)
Satisﬁed 57 (57.6)
Unsatisﬁed 1 (1.0)
Very unsatisﬁed 0 (0.0)
Participant's perception of treatment difﬁculty
Not at all difﬁcult 77 (77.0)
Somewhat difﬁcult 15 (15.0)
Difﬁcult 0 (0.0)
Very difﬁcult 3 (3.0)
Not sure 5 (5.0)
Participant's perception of amount of bleeding experienced
Less than expected 62 (62.0)
More than expected 11 (11.0)
As expected 20 (20.0)
Do not know 7 (7.0)
Participant's rating of acceptability of bleeding
Very acceptable 22 (22.0)
Acceptable 76 (76.0)
Not acceptable 0 (0.0)
Do not know 2 (2.0)
Participants' perception of pain experienced
Very tolerable 16 (16.0)
Tolerable 75 (75.0)
No pain 5 (5.0)
Not tolerable 2 (2.0)
Do not know 2 (2.0)
Received enough medication (n=95)
Yes 55 (57.9)
No 40 (42.1)
Pain level compared with previous surgical evacuation c (n=21)
Less painful 16 (76.2)
As painful 0 (0.0)
More painful 2 (9.5)
Do not know 3 (14.3)
Comparison to previous surgical evacuation c (n=21)
Better 20 (95.2)
Same 0 (0.0)
Worse 0 (0.0)
Do not know 1 (4.8)
a Values are given as number (percentage).
b Outcome data unavailable for 1 woman but all available data analyzed.
c Among women reporting previous surgical evacuation.
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as “tolerable.”
When asked about the perceived difﬁculty of misoprostol treat-
ment, 77 (77.0%) women characterized it as “not at all difﬁcult” and
15 (15.0%) as “somewhat difﬁcult.”Womenwere also asked who pro-
vided counseling and whether they believed this counseling covered
all aspects of treatment. Ninety-six of 98 (98.0%) women indicated
that a nurse–midwife provided counseling, and 98 (100.0%) reported
that the counseling covered all aspects of treatment. Of the 21 (21.9%)women reporting a previous surgical evacuation, 16 (76.2%) reported
that treatment with misoprostol was “less painful” and 20 (95.2%)
characterized the study treatment as “better.” Ninety-seven of 99
(98.0%) participants indicated that they would choose the misopros-
tol and 95 of 97 (97.9%) stated that they would recommend it to a
friend.
4. Discussion
These results demonstrate that 400-μg sublingual misoprostol is a
safe, effective, and acceptable option for uterine evacuation at
lower-level health facilities with no previous experience providing
postabortion care. Indeed, nearly all women in the study experienced
successful uterine evacuation after receiving 2 tablets of misoprostol.
The adverse effects of the drug were considered to be tolerable by
most women and, apart from expected bleeding and abdominal pain/
cramps, few effects were reported—resulting in a very high satisfaction
proﬁle for this simple medical treatment.
The integration of misoprostol into postabortion care service deliv-
ery at all levels of the healthcare system can positively contribute to
larger efforts focused on shifting certain medical tasks to trained mid-
level providers who, in many instances, are closer to the women need-
ing care. Indeed, before the present study, women in Burkina Faso
presenting at lower-level facilities and requiring uterine evacuation for
postabortion complications were systematically referred to the closest
tertiary facility for treatment—a journey that would, in many instances,
require at least 1 day of travel away from home. The potential
cost-effectiveness of misoprostol treatment for incomplete abortion
has been previously documented [10,11]. In the case of Burkina Faso, ac-
cess tomisoprostol care locally enabledwomen to save time andmoney
because they were able to receive care at their ﬁrst point of service. Fur-
thermore, it empoweredmedical staff at lower levels of care to be able to
provide a simple and effective treatment for incomplete abortion.
It has been argued that ultrasound and surgical skills are needed
to provide uterine evacuation services safely and effectively. The
experience at the 2 facilities in Burkina Faso documents successful
service delivery with neither ultrasound nor surgical skills/equipment.
Indeed, providers relied on standard referral services to manage the
7.1% of women for whom they felt ultrasonography may be helpful to
ascertain incomplete abortion status and complete uterine evacuation.
The existing referral system was used to manage care for women
requiring additional surgical back-up. Patient carewas not compromised
in either instance. By using the referral system for back-up instead of sys-
tematic care for all women, the majority of postabortion care services
were provided at little additional cost at these lower-level facilities.
Despite the promise of these results, their applicability may be lim-
ited by the fact that recruitment occurred at only 2 facilities in 1 coun-
try. The programmatic and logistic challenges in other countries and
settings may be different. Moreover, treatment was provided in the
context of a study, so care, counseling, and attention to follow-up may
not reﬂect actual day-to-day clinical realities outside of a study setting.
Nonetheless, the documentation of the present successful experience
can serve as an example for other countries interested in pursuing sim-
ilar programs aimed at expanding the reach of postabortion care.
Although there has been considerable progress in expanding access
to non-surgical methods of postabortion care over the past 10 years,
there is still much room for improvement. Indeed, although a recent
publication [12] on scaling-up postabortion care made curiously little
mention of medical management—despite the copious availability of
evidence and the inclusion of misoprostol on the WHO Model List of
Essential Medicines [9] for this indication—the authors did advocate
for continued momentum to expand access to postabortion care.
There is ample clinical evidence of high safety, efﬁcacy, and satisfaction
rates with this method [2–8] and a favorable policy climate, given the
inclusion of misoprostol on the Model List of Essential Medicines and
recommendations by FIGO [13]. The time has now come to scale-up
169T. Blandine et al. / International Journal of Gynecology and Obstetrics 119 (2012) 166–169access to the service by training providers and making the medication
more widely available. The experience in Burkina Faso should serve as
an impetus for the introduction of misoprostol as ﬁrst-line treatment
for postabortion care in health systems globally.
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